BCAR3 and neoplasm: While elevated BCAR3 levels in TNBC and HNSCC are associated with increased tumor aggressiveness and poorer outcomes, its diminished expression in Luminal A and B subtypes correlates with resistance to endocrine therapy and worse prognosis.